Kimberly I. Chew – Husch Blackwell

Kimberly is a leading member of the psychedelic law practice group at Husch Blackwell. As a former research scientist for biotech startups, Kimberly has a unique perspective in the emerging area of psychedelic therapeutics. She keeps current on the academic and commercial research and drug discovery efforts in this rapidly changing field, such as the development of medicines for PTSD and treatment-resistant depression. Kimberly assists psychedelics clients in navigating and complying with complex regulatory issues and protecting and commercializing intellectual property. She has a particular focus on issues involved with clinical trials involving Schedule I drugs in the United States.While psychedelic drugs such as MDMA, psilocybin, LSD and DMT are currently federally illegal Schedule 1 substances, the FDA is currently overseeing Phase I, II and III studies exploring the potential therapeutic benefit of these drugs. Members of the Husch Blackwell psychedelic law team are closely following this progress and concurrent proposed state legislation in multiple jurisdictions, and are positioned to help clients navigate what will no doubt be highly complex and novel legal issues.

Alongside her psychedelics practice, Kimberly works with the firm’s Asbestos Litigation team, helping clients manage their risk profiles in complex product liability issues and defending large national dockets. She coordinates discovery for thousands of cases and also advises clients on related environmental law.

Publications:

• Protecting the Science and Innovation of Psychedelics :- https://microdose.buzz/news/protecting-the-science-and-innovation-of-psychedelics/
• Speaking Engagement: “FDA regulatory guidance,” 2022 Psychedelic Therapeutic & Drug Development Conference :- https://www.huschblackwell.com/newsandinsights/speaker-fda-regulatory-guidance-2022-psychedelic-therapeutics-drug-development-conference

Social Media:

• LinkedIn